Canvas Wealth Advisors LLC Takes $470,000 Position in Becton, Dickinson and Company $BDX

Canvas Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,571 shares of the medical instruments supplier's stock, valued at approximately $470,000.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after purchasing an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 3.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after purchasing an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after purchasing an additional 667,957 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Becton, Dickinson and Company by 7.6% in the 1st quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock valued at $1,012,649,000 after purchasing an additional 312,124 shares during the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Becton, Dickinson and Company by 0.4% in the 2nd quarter. Nordea Investment Management AB now owns 3,365,509 shares of the medical instruments supplier's stock valued at $577,420,000 after purchasing an additional 12,602 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on BDX shares. Weiss Ratings reissued a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Argus increased their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Piper Sandler reissued a "neutral" rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $205.40.

Becton, Dickinson and Company Stock Performance

BDX opened at $189.20 on Monday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company's fifty day moving average price is $190.60 and its two-hundred day moving average price is $184.37. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a market cap of $54.23 billion, a price-to-earnings ratio of 34.03, a PEG ratio of 1.48 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. On average, analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Insiders Place Their Bets

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 1,838 shares of company stock worth $348,392 in the last 90 days. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.